Medicaid Managed Care Open Enrollment Extended through Dec. 15
Current Suspected Overdose Deaths in Delaware for 2017: 225
Delaware’s Division of Public Health (DPH) was notified Dec. 4 that routine testing by the Centers for Disease Control and Prevention (CDC) identified oseltamivir (Tamiflu) resistant H1N1 influenza in a laboratory sample taken from a 52-year-old Kent County resident. This is the only known oseltamivir resistant influenza infection known to date in a Delaware resident.
CDC has tested a total of 1,540 specimens submitted nationally, of which 15 were found resistant to oseltamivir. Because oseltamivir resistence is infrequent, DPH is not proposing changes to previous antiviral recommendations (http://dhss.delaware.gov/dhss/dph/php/alerts/dhan201.html).
However, DPH is recommending that clinicians consider treatment with zanamivir (Relenza) if patients are not responsive to oseltamivir. In addition, Peramivir should be considered for hospitalized patients who are seriously ill or who are not responding to either oseltamivir or zanamivir (http://dhss.delaware.gov/dhss/dph/php/alerts/dhan206.html).
Questions about this health alert should be directed to DPH’s Immunization Program at 1-800-282-8672.
You are receiving this email because you are a registered member of the Delaware Health Alert Network. If you are not a member and would like to subscribe, please register at https://www.healthalertde.org/.